Relay Therapeutics, Inc. (RLAY)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-06) · 99.1 · 99.2 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-05) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-02-26) · 99.1 | ||
| 10-Q | Q3-2025 | 8-K (2025-11-06) · 99.1 | ||
| 10-Q | Q2-2025 | 8-K (2025-08-07) · 99.1 | ||
| 10-Q | Q1-2025 | 8-K (2025-05-05) · 99.1 | ||
| 10-K | FY-2024 | 8-K (2025-02-26) · 99.1 | ||
| 10-Q | Q3-2024 | 8-K (2024-11-06) · 99.1 | ||
| 10-Q | Q2-2024 | 8-K (2024-08-06) · 99.1 | ||
| 10-Q | Q1-2024 | 8-K (2024-05-02) · 99.1 | ||
| 10-K | FY-2023 | 8-K (2024-02-22) · 99.1 | ||
| 10-Q | Q3-2023 | 8-K (2023-11-02) · 99.1 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations and Comprehensive Loss | ||
| Consolidated Statements of Stockholders' Equity | ||
| Consolidated Statements of Cash Flows | ||
| Consolidated Statements of Cash Flows (P) | ||
| Notes | ||
| Accrued Expenses | — |
|
| Acquisition of Zebiai | — |
|
| Collaboration and License Agreement With Genentech, Inc. | — |
|
| Collaboration and License Agreements | — |
|
| Collaboration and License Arrangements | — |
|
| Commitments and Contingencies | ||
| Common Stock | ||
| Cybersecurity Risk Management, Strategy and Governance | — |
|
| Employee Benefits | — |
|
| Fair Value Measurements | ||
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Investments | ||
| Leases | — |
|
| License Agreements | — |
|
| Long-lived Assets | — |
|
| Nature of Business and Basis of Presentation | ||
| Net Loss Per Share | ||
| Operating Leases | — |
|
| Pay Vs Performance Disclosure | ||
| Property and Equipment | — |
|
| Segment Information | ||
| Significant Accounting Policies | ||
| Stock Compensation | ||
| Subsequent Events | ||